FibroGen is a biotechnology company committed to developing drugs for fibrotic disease, anemia, conditions associated with tissue damage or injury, and cancer through scientific leadership in HIF biology and tissue fibrosis.

August 29, 2008
Toshinari Tamura, Ph.D., Joins Board of Directors of FibroGen, Inc.

January 22, 2008
FibroGen Reports New Research on Development of HIF Prolyl Hydroxylase Inhibitors Related to Endothelial Progenitor Cells, Anti-Inflammation, Cytoprotection and Erythropoiesis

November 7, 2007
FibroGen Announces New Research in HIF and CTGF Therapeutic Programs Presented at the Annual Meeting of the American Society of Nephrology

February 13, 2007 - FibroGen Appoints Sarah A. O'Dowd, Vice President & General Counsel

February 9, 2007 - FibroGen Reports Pharmacologic Stabilization of Hypoxia-Inducible Factor (HIF) Prevents Brain Tissue Damage and Preserves Motor Function in a Preclinical Model of Transient Ischemic Stroke

November 17, 2006 - FibroGen Reports Results of a Phase 1b Study of FG-3019, Therapeutic Antibody Against CTGF, in Diabetic Patients with Microalbuminuria

See All Press Releases/Events

FG-3019	>	Diabetic nephropathy

	>	Idiopathic pulmonary fibrosis

	>	Focal segmental glomerulosclerosis

	>	Pancreatic cancer

FG-2216	>	Anemia

FG-4592	>	Anemia of chronic inflammatory disease

FG-4539	>	Cytoprotection

FG-5030, FG-5017
	>	Dermal fillers

Introduction for Patients

FG-3019: Diabetic nephropathy

FG-2216: Anemia

HIF Stabilization (erythropoiesis, cytoprotection, metabolism, vascular biology)

Anti-CTGF (fibrosis, diabetic complications)

TGF-Beta Inhibition (fibrosis, cancer)

CTGF/CCN Inhibition (tumor metastases)



	Recombinant Collagens
		Synthetic Gelatins Vaccine / Biologic Stabilizer Capsule Gelatins

Home I About Us I Pipeline I R&D I Clinical Trials I News & Events



FibroGen, Inc., 225 Gateway Blvd., South San Francisco, CA 94080 Phone: 650-866-7200, Fax: 650-866-7202, Email: info@fibrogen.com
FibroGen 2008 ©